Johnson & Johnson (JNJ)
270.47
+3.33 (1.25%)
NYSE · Last Trade: Nov 22nd, 10:14 AM EST
Johnson & Johnson Is on Track for $101 Billion in 2026 Sales. Is This Dividend King Still a Buy?fool.com
J&J is a healthcare giant performing very well right now, but it won't be a great fit for every investor.
Via The Motley Fool · November 22, 2026
Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027?fool.com
Johnson & Johnson's drug-and-device product mix faces off against Pfizer's high-stakes oncology and obesity bets, with a valuation gap that may sway your choice.
Via The Motley Fool · November 22, 2026
Johnson & Johnson Delivered 'Immaculate' Prostate Cancer Data at ESMO. Here's Why Investors Should Carefool.com
Johnson & Johnson's $3.05 billion Halda bet is already paying off in the clinic.
Via The Motley Fool · November 19, 2026
Dow Jones Losers Today: NIKE and UnitedHealth Lead Declineschartmill.com
Via Chartmill · November 19, 2026
Dow Jones Decliners: UNH, NKE, CAT Lead Today's Sessionchartmill.com
Via Chartmill · November 19, 2026
Johnson & Johnson (NYSE:JNJ): A Dividend Quality Case Study for Income Investorschartmill.com
Via Chartmill · November 9, 2026
Johnson & Johnson vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?fool.com
Johnson & Johnson's diversified MedTech and pharma mix faces off against Vertex's cystic fibrosis dominance, but their valuation gap tells a story worth weighing.
Via The Motley Fool · November 17, 2026
2 of the Best Dividend Stocks to Buy With $5,000 in Novemberfool.com
These two dividend stocks offer reliable raises year after year.
Via The Motley Fool · November 17, 2026
Johnson & Johnson vs. Pfizer: Consistency vs. Volatility in Revenuefool.com
J&J's quarterly sales have climbed with few setbacks, while Pfizer's have swung between $13.7 billion and $17.8 billion over eight quarters.
Via The Motley Fool · November 17, 2026
Johnson & Johnson vs. Novo Nordisk: Steady Uptrend vs. Flat Revenuefool.com
Johnson & Johnson's revenue has climbed quarter after quarter, while Novo Nordisk's has stayed largely flat apart from one notable jump.
Via The Motley Fool · November 17, 2026
5 Dividend Stocks to Buy and Hold Foreverfool.com
These five stocks have proven track records of dividend growth backed by attractive businesses.
Via The Motley Fool · November 14, 2026
These 5 Dividend Aristocrats® Have Raised Payouts for Decadesfool.com
Investors worried about market turmoil may want to look at reliable dividend stocks, and these five stand out.
Via The Motley Fool · November 11, 2026
Johnson & Johnson vs. Eli Lilly: Which Healthcare Giant's Stock Is a Better Buy for 2027?fool.com
Eli Lilly's sales jumped 44.7% last year, while Johnson & Johnson's steadier profile raises a different question for cautious portfolios.
Via The Motley Fool · November 11, 2026
Johnson & Johnson Sees a Path to Double-Digit Growth by 2030. Is the Dividend King a Buy?fool.com
The business has undergone major changes in recent years, and these might pay off over the medium term.
Via The Motley Fool · November 11, 2026
The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boommarketbeat.com
AI infrastructure is being funded with debt and stock sales while biotech companies applying AI are booking revenue, led by Tempus AI, Recursion and iShares Biotechnology
Via MarketBeat · November 11, 2026
Stocks Fell After the Midterms. History Says the Next 12 Months Could Be Very Differentfool.com
Keep focusing on the long term.
Via The Motley Fool · November 10, 2026
Stock Market Sell-Off: Meet the Unstoppable Vanguard ETF Obliterating the S&P 500 in 2026fool.com
Value stocks are crushing growth stocks as investors sour on the artificial intelligence trade.
Via The Motley Fool · November 10, 2026
The Buffett Indicator Is Flashing Red. These 3 Dividend Stocks Could Be Safe Havens.fool.com
The stock market is looking overvalued, according to this indicator.
Via The Motley Fool · November 10, 2026
4 Stocks I'm Not Selling Even If the Fed Keeps Raising Ratesfool.com
Some companies will perform pretty well regardless of whether or not interest rates rise.
Via The Motley Fool · November 6, 2026
2 Growth Stocks to Buy in November Without Any Hesitationfool.com
They have both outperformed the broader equity market over the long run.
Via The Motley Fool · November 5, 2026
Worried About an AI Bubble? This ETF Could Be the Smartest Buy Right Nowfool.com
This ETF offers a smart middle ground for investors anxious about the AI trade but who don't want to sit on the sidelines.
Via The Motley Fool · November 3, 2026
The Best Dividend Stocks to Buy With $5,000 in Novemberfool.com
AbbVie, J&J, and Medtronic remain reliable dividend plays in a rough market.
Via The Motley Fool · November 2, 2026
Intuitive Surgical Stock Just Fell Despite a 22% Revenue Jump. Here's What Investors Are Missing.fool.com
Selling surgical robots is not the largest source of Intuitive Surgical's revenue.
Via The Motley Fool · November 1, 2026
Medtronic Just Retired 55 Million Shares Without Spending Cash. Is the Stock a Buy?fool.com
Medtronic grew revenue by 14% in the first quarter of its fiscal 2027.
Via The Motley Fool · November 1, 2026
If a Bear Market Is Coming, History Says These Stocks Could Be the Smartest to Ownfool.com
Consumers don't stop buying vital products during bear markets, which is why healthcare and consumer staples stocks are smart investments.
Via The Motley Fool · October 31, 2026
